Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Feature|Articles|August 6, 2025
Top 5 urologic oncology headlines you missed in July 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.
Advertisement
Advertisement
July 2025 brought a wave of significant advancements in urologic oncology, highlighting the continued innovation transforming the field. Major updates spanned prostate, bladder, and kidney cancers—reflecting progress across the spectrum of care.
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Advertisement
Advertisement